WASHINGTON — Four months after a mysterious new virus began its deadly march around the globe, the search for a vaccine has taken on an intensity never before seen in medical research, with huge implications for public health, the world economy and politics.

Seven of the roughly 90 projects being pursued by governments, pharmaceutical makers, biotech innovators and academic laboratories have reached the stage of clinical trials. With political leaders — not least President Trump — increasingly pressing for progress, and with big potential profits at stake for the industry, drug makers and researchers have signaled that they are moving ahead at unheard-of speeds.

Continue reading “Profits and Pride at Stake, the Race for a Vaccine Intensifies” →

The New York Times, May 1, 2020

Link

The world is eager to come out of lockdown. But if countries simply return to business as usual, new outbreaks of Covid-19 will follow. The only solution that public health experts see is to keep careful track of the coronavirus and clamp down on new flare-ups.

The trouble is that the most obvious way to monitor the virus — testing person by person — has already proved to be a huge, expensive challenge. Experts say we’re nowhere near the scale we need to get a good picture of the pandemic.

Continue reading “Is It Safe to Come Out of Lockdown? Check the Sewer” →

The New York Times, April 30, 2020

Link

In the early 1950s, psychiatrists began treating schizophrenia with a new drug called chlorpromazine. Seven decades later, the drug is still used as an anti-psychotic.

But now scientists have discovered that the drug, also known as Thorazine, can do something entirely different. It can stop the new coronavirus that causes Covid-19 from invading cells.

Driven by the pandemic’s spread, research teams have been screening thousands of drugs to see if they have this unexpected potential to fight the coronavirus. They’ve tested the drugs on dishes of cells, and a few dozen candidates have made the first cut.

Continue reading “Old Drugs May Find a New Purpose: Fighting the Coronavirus” →

The New York Times, April 8, 2020

Link

New research indicates that the coronavirus began to circulate in the New York area by mid-February, weeks before the first confirmed case, and that travelers brought in the virus mainly from Europe, not Asia.

“The majority is clearly European,” said Harm van Bakel, a geneticist at Icahn School of Medicine at Mount Sinai, who co-wrote a study awaiting peer review.

A separate team at N.Y.U. Grossman School of Medicine came to strikingly similar conclusions, despite studying a different group of cases. Both teams analyzed genomes from coronaviruses taken from New Yorkers starting in mid-March.

Continue reading “Most New York Coronavirus Cases Came From Europe, Genomes Show” →